MEDXF 财务： Medexus Pharmaceuticals Inc. AI 分析

Q: Medexus Pharmaceuticals Inc. 的关键财务报表是什么？

根据最新的财务报表（Form-10K），Medexus Pharmaceuticals Inc. 的总资产为 $171，净利润为 $2

Q: MEDXF 的关键财务比率是什么？

Medexus Pharmaceuticals Inc. 的流动比率是 1.43，净利 margin 为 1.85，每股销售为 $4.07。

Q: Medexus Pharmaceuticals Inc. 的收入按细分市场或地理位置如何划分？

Medexus Pharmaceuticals Inc. 最大收入来源是 Retail & Commercial，在最近的收益报告中收入为 607,890。就地区而言， Canada 是 Medexus Pharmaceuticals Inc. 的主要市场，收入为 610,168。

Q: Medexus Pharmaceuticals Inc. 是否盈利？

是的，根据最新的财务报表，Medexus Pharmaceuticals Inc. 的净利润为 $2

Q: Medexus Pharmaceuticals Inc. 有负债吗？

是的，Medexus Pharmaceuticals Inc. 的负债为 119

Q: Medexus Pharmaceuticals Inc. 的流通股有多少？

Medexus Pharmaceuticals Inc. 的总流通股为 32.25

主页

股票

MEDXF

MEDXF 财务

Medexus Pharmaceuticals Inc.

$2.08

-1.79%

$-0.03

截至今日：Jan 29, 10:47:30 GMT-5

概述预测收益股息财务数据

关键数据

前收盘价

$2.12

开盘价

$2.04

当日区间

$2.03 - $2.08

52周范围

$1.43 - $2.78

交易量

3.1K

平均成交量

15.7K

每股收益（TTM）

0.01

股息收益率

市值

$67.4M

什么是 Medexus Pharmaceuticals Inc？

Medexus Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products and treatment solutions focusing on therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. The company is headquartered in Toronto, Ontario and currently employs 91 full-time employees. The company went IPO on 2012-03-03. The firm has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. The company operates through two product portfolios: Medexus Pharma Canada and Medexus Pharma. Its lead products are IXINITY (US), GRAFAPEX (US), Trecondyv (Canada), Rupall (Canada), Rasuvo (US), Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

功能特性

交易策略

资源

市场

收入

资产负债表

现金流量

年度

季度性

MEDXF 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	03/31/2025	03/31/2024	03/31/2023	03/31/2022	03/31/2021
营收	104	108	113	108	76	79
营收同比增长 (YoY)	0%	-4%	5%	42%	-4%	7%
营收成本	48	51	53	48	38	37
毛利润	55	56	59	60	37	42
销售、一般及管理费用	47	43	44	48	44	36
研发	1	1	1	2	5	4
营业费用	49	44	46	51	50	42
其他非经营性收入 (费用)	--	--	--	--	--	--
税前利润	0	1	0	-5	-3	-31
所得税费用	0	0	0	-6	0	-3
净利润	0	2	0	1	-2	-28
净利润增长	-100%	--	-100%	-150%	-93%	367%
稀释后流通股数	32.28	26.5	22.32	20.52	19.45	15.2
股份同比变动 (YoY)	32%	19%	9%	6%	28%	6%
每股收益 (摊薄)	0.01	0.08	0	0.05	-0.14	-1.86
每股收益增长率	-82%	-983%	-115.99%	-140%	-92%	333%
自由现金流	13	21	18	-1	-8	-5
每股自由现金流	--	--	--	--	--	--
毛利率	52.88%	51.85%	52.21%	55.55%	48.68%	53.16%
营业利润率	4.8%	10.18%	10.61%	7.4%	-15.78%	0%
净利率	0%	1.85%	0%	0.92%	-2.63%	-35.44%
自由现金流利润率	12.5%	19.44%	15.92%	-0.92%	-10.52%	-6.32%
EBITDA	14	18	17	14	-6	5
EBITDA 利润率	13.46%	16.66%	15.04%	12.96%	-7.89%	6.32%
EBITDA 中的折旧与摊销	9	7	5	6	6	5
EBIT	5	11	12	8	-12	0
EBIT 利润率	4.8%	10.18%	10.61%	7.4%	-15.78%	0%
有效税率	0%	0%	0%	120%	0%	9.67%

Follow-Up Questions

Medexus Pharmaceuticals Inc. 的关键财务报表是什么？



MEDXF 的关键财务比率是什么？



Medexus Pharmaceuticals Inc. 的收入按细分市场或地理位置如何划分？



Medexus Pharmaceuticals Inc. 是否盈利？



Medexus Pharmaceuticals Inc. 有负债吗？



Medexus Pharmaceuticals Inc. 的流通股有多少？



Medexus Pharmaceuticals Inc.（MEDXF）价格

MEDXF 股价走势图